Target intelligence / Profile preview

Human immunodeficiency virus type 1 glycoprotein 41 membrane-proximal external region (HIV-1 gp41 MPER) (HIV-1 gp41 MPER)

Target
HIV-1 gp41 MPER
Molecular classification
Viral envelope protein, Fusion protein, Transmembrane protein
01

Overview

The HIV-1 gp41 membrane-proximal external region (MPER) is a highly conserved, tryptophan-rich sequence located at the C-terminal end of the gp41 ectodomain, immediately preceding the transmembrane domain (Montero et al., 2008, PMID: 18772287). During HIV-1 entry, the envelope glycoprotein complex (gp120/gp41) undergoes conformational changes upon binding to CD4 and coreceptors, leading to the formation of a transient pre-hairpin intermediate where the MPER is exposed (Frey et al., 2008, PMID: 18332424). This intermediate state is a critical target for broadly neutralizing antibodies (bNAbs) such as 2F5, 4E10, and 10E8, which bind to the MPER and block the transition to the post-fusion six-helix bundle, thereby preventing viral-cell membrane fusion (Huang et al., 2012, PMID: 23151583). Because the MPER is essential for the fusion process and is highly conserved across diverse HIV-1 strains, it is a primary focus for vaccine design and the development of fusion-inhibitor drugs (Kim et al., 2014, PMID: 24501411). However, therapeutic targeting is complicated by the MPER's close proximity to the viral lipid bilayer and its limited accessibility during the short-lived pre-hairpin stage (Ofek et al., 2004, PMID: 15548732).

Other names
MPERgp41 MPERMembrane-proximal external regionHIV-1 gp41 pre-hairpin intermediategp41 MPER epitope
02

Mechanism of action

Inhibition of viral-cell membrane fusion by binding to the transiently exposed pre-hairpin intermediate of gp41, preventing the formation of the six-helix bundle (Zhu et al., 2013, PMID: 23596311).

03

Biological functions

Viral entryMembrane fusionViral-host cell attachment
04

Disease associations

Infection
05

Safety considerations

Viral escape mutations (Boutonnet et al., 2009, PMID: 19439567)Potential lipid cross-reactivity/autoreactivity (Haynes et al., 2005, PMID: 15845877)Transient epitope accessibility (Ofek et al., 2004, PMID: 15548732)
06

Interacting drugs

10E8 (broadly neutralizing antibody)

4 more in the full profile.

07

Biomarkers

HIV-1 RNA viral loadCD4+ T-cell countMPER-specific antibody titers

Beyond the preview

Go deeper on Human immunodeficiency virus type 1 glycoprotein 41 membrane-proximal external region (HIV-1 gp41 MPER) (HIV-1 gp41 MPER).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human immunodeficiency virus type 1 glycoprotein 41 membrane-proximal external region (HIV-1 gp41 MPER) (HIV-1 gp41 MPER).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call